The stock will trade on the MBX 4291 obesity data and the Phase 3 canvuparatide catalyst. The Q4 2026 12-week MAD data for MBX 4291 is the next major binary event. The earnings miss is irrelevant for a pre-revenue biotech; focus on pipeline execution.
Price Chart
Executive Summary
MBX Biosciences reported Q2 2026 results with a net loss of $0.78 per share, significantly missing the consensus estimate of $-0.59. The company highlighted key pipeline progress: initial Phase 1 data for obesity candidate MBX 4291 showed 7% mean weight loss at 8 weeks with good tolerability, supporting once-monthly dosing potential, and the Phase 3 trial for canvuparatide in hypoparathyroidism is now recruiting. Despite the earnings miss, the positive clinical data and strong cash position of $418.6 million (runway into 2029) are the primary drivers for the stock.
Key Financial Metrics
Key Facts
- Net loss per share was $-0.78, missing consensus of $-0.59 (-33.2% miss).
- Cash, cash equivalents and marketable securities of $418.6 million as of June 30, 2026, expected to fund operations into 2029.
- Initial Phase 1 data for MBX 4291 (GLP-1/GIP prodrug for obesity) showed 7% mean weight loss at 8 weeks with no nausea or vomiting.
- Phase 3 pivotal trial (oPTimize) for once-weekly canvuparatide in hypoparathyroidism is now recruiting.
- Nomination of two new preclinical obesity candidates: MBX 6180 (GLP-1/GIP/GCG triple agonist) and MBX 5765 (amycretin prodrug).
Financial Impact
Net loss of $37.1 million in Q2 2026, compared to $19.4 million in Q2 2025, driven by increased R&D and G&A spending.
Risk Factors
- Clinical trial failure risk for canvuparatide and MBX 4291.
- Competitive landscape in obesity (Novo Nordisk, Eli Lilly, other biotechs).
- Cash burn rate is accelerating ($37.1M net loss in Q2 vs $23.5M in Q1 2026), potentially requiring future capital raises.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-336841 |
| Document: mbx-20260806.htm | 0001193125-26-336841 |
| Document: mbx-ex99_2.htm | 0001193125-26-336841 |
| Document: 0001193125-26-336841-index-headers.html | 0001193125-26-336841 |
| Document: 0001193125-26-336841-index.html | 0001193125-26-336841 |
| Document: 0001193125-26-336841.txt | 0001193125-26-336841 |
| 8-K Data (Synthetic) | 0001193125-26-336841 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 3 | $50.46 $48.50 | ▼ −3.88% | ▼ −3.36% | $50.29 (−0.34%) |
Oct 22, 2026 4d ago | 8-K | $50.46 $48.50 | ▼ −3.88% | ▼ −3.36% | $50.29 (−0.34%) |
Aug 27, 2026 8w ago | Press Release | $66.39 $63.00 | ▼ −5.11% | ▼ −4.88% | $50.29 (−24.25%) |
Aug 17, 2026 10w ago | 144 | $68.25 $66.52 | ▼ −2.53% | ▼ −1.86% | $50.29 (−26.32%) |
Aug 6, 2026 11w ago | 8-K | $67.11 $67.82 | ▲ +1.06% | ▲ +0.45% | $50.29 (−25.06%) |
Jun 12, 2026 19w ago | 8-K | $35.51 $38.98 | ▲ +9.77% | ▲ +8.01% | $50.29 (+41.62%) |
Jun 12, 2026 19w ago | Press Release | $35.51 $38.98 | ▲ +9.77% | ▲ +8.01% | $50.29 (+41.62%) |
Jun 11, 2026 19w ago | Institutional Cluster | $37.25 $35.51 | ▼ −4.67% | ▼ −5.21% | $50.29 (+35.01%) |
Jun 11, 2026 19w ago | Institutional Cluster | $37.25 $35.51 | ▼ −4.67% | ▼ −5.21% | $50.29 (+35.01%) |
Jun 10, 2026 19w ago | 144 | $30.99 $37.25 | ▲ +20.20% | ▲ +18.50% | $50.29 (+62.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers